Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200–499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study

Despite reducing progression and promoting regression of coronary atherosclerosis, statin therapy does not fully address residual cardiovascular (CV) risk. High‐purity eicosapentaenoic acid (EPA) added to a statin has been shown to reduce CV events and induce regression of coronary atherosclerosis i...

Descripción completa

Detalles Bibliográficos
Autores principales: Budoff, Matthew, Brent Muhlestein, J., Le, Viet T., May, Heidi T., Roy, Sion, Nelson, John R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2018
Materias:
Trial Designs
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838559/
https://www.ncbi.nlm.nih.gov/pubmed/29365351
http://dx.doi.org/10.1002/clc.22856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838559/
https://www.ncbi.nlm.nih.gov/pubmed/29365351
http://dx.doi.org/10.1002/clc.22856

Ejemplares similares